REGISTER NOW WITH HYPERTENSION CARE
Sign up to receive information through Hypertension Care, including educational materials and other resources for your patients.Register Here
Daiichi Sankyo, Inc. ("Daiichi Sankyo") maintains this site for your personal information, education, and communication. While you are free to browse the site, your access to and use of the site is subject to the following terms and conditions ("Terms and Conditions") and all applicable laws. By accessing and browsing the site, you accept, without limitation or qualification, the Terms and Conditions.
Terms and conditions
Copyrights and Trademarks
The contents of this site are protected under applicable copyright and trademark laws. Except as otherwise set forth on the website, all images and text are owned by or licensed to Daiichi Sankyo and, except as provided within these Terms and Conditions, may not be downloaded, distributed, stored, reused, reposted, modified, or otherwise used without the express written permission of Daiichi Sankyo. Daiichi Sankyo neither warrants nor represents that your use of material displayed on the site will not infringe rights of third parties.
You may print a single copy of the content for your own personal, non-commercial use, provided you also retain all copyright and other proprietary notices contained in the materials or as specified on the site. The further use, re-use, copying, distribution, redistribution, modification, publication, or re-posting of or to any part of this site (including the text, images, audio, and video) is strictly prohibited and nothing contained on this site should be construed as granting, by implication, estoppel, or otherwise, any license or right to use any Daiichi Sankyo intellectual property right (including, but not limited to any patent, trademark, trade name, copyright, or trade secret).
Special Note Regarding Website Use By Children
The website is neither directed at nor designed for use by children (ie, anyone under 18 years old).
This site is controlled and operated from the United States. The information on this site is designed to comply with the laws of the United States and is intended for use by US residents only. Daiichi Sankyo makes no representation that materials in this site are appropriate or applicable for use in other countries. The information provided on this site is for general educational and informational purposes only. Such information is not meant to be a substitute for advice provided by a physician or other qualified healthcare professional. PLEASE CONSULT WITH YOUR DOCTOR OR OTHER HEALTHCARE PROFESSIONAL BEFORE USING ANY DRUG PRODUCT DISCUSSED WITHIN THIS SITE.
While Daiichi Sankyo uses reasonable care to ensure that information is accurate at the time it is added on this site, the contents of this site are provided to you "AS IS," WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT and Daiichi Sankyo makes no representations as to the availability, accuracy, or completeness of the content of this site. Daiichi Sankyo may make changes to these materials at any time, without notice, and makes no commitment to update the information contained herein. Daiichi Sankyo shall not be liable for any damages or injury resulting from your access to, or inability to access, this site or from your reliance on any information at this site or for any viruses that may infect your computer equipment or other property on account of your access to, use of, or browsing in this site or your downloading of any materials, data, text, images, video, or audio from this site.
Links to Other Sites
Our site may provide links or references to other websites not affiliated with Daiichi Sankyo. Daiichi Sankyo believes its links provide helpful information; however, Daiichi Sankyo is not responsible for the content of such other sites and shall not be liable for any damages or injury arising from your access to such sites. Links to other sites are provided only as a convenience to users of our site.
Collection and Use of Your Personal Information
Daiichi Sankyo may collect data from you that you provide to us voluntarily such as your name, postal address, email address, telephone number, and other personal information. The information you provide is used to contact you, via email or by regular mail, to provide you with information that we believe may be of interest to you. We do not sell or transfer the information you send to us to others outside our company, except that your data may be transferred to various outside companies or agents working on behalf of Daiichi Sankyo to help fulfill business transactions and to Daiichi Sankyo's affiliates. However, Daiichi Sankyo will not share any of your personal information with third parties for their own marketing use unless you explicitly give us permission to do so.
Automatically Collected Information
Daiichi Sankyo automatically collects certain types of information whenever you interact with us on this site and in some emails we may send each other. Automatic technologies we use may include, for example, web server logs and IP addresses, cookies, and web beacons.
Web Server Logs and IP Addresses: An IP address is a unique identifying number that is automatically assigned to any computer connected to the Internet. Depending on the nature of your Internet connection, the IP address may change each time you connect or may always be the same number for that computer. Daiichi Sankyo reserves the right to log IP addresses for system administration, security, statistical analysis, demographic analysis of website use, and other functions.
Web Beacons: On certain web pages or emails, Daiichi Sankyo may utilize a common Internet technology called a "web beacon" (also known as an "action tag" or "clear GIF technology"). Web beacons help analyze the effectiveness of websites by measuring, for example, the number of visitors to a site or how many visitors clicked on key elements of a site.
Web beacons, cookies, and other tracking technologies do not automatically obtain personal information about you. Only if you voluntarily submit personal information, such as by registering or sending emails, can these automatic tracking technologies be used to provide further information about your use of the websites to improve their usefulness to you.
To the extent that this site makes forums, message boards and/or news groups available to you, please remember that any information that is disclosed in these areas becomes public information. You should exercise caution in disclosing personally identifying information there or in any other public section of the Internet.
Feedback and Suggestions
Daiichi Sankyo welcomes your feedback and suggestions about how to improve this site. Any ideas, suggestions, information, know-how, material, or other content (collectively, "content") received through this site, however, will be deemed to include a royalty-free, perpetual, irrevocable, transferable, worldwide, nonexclusive right and license for Daiichi Sankyo to adopt, publish, reproduce, disseminate, transmit, distribute, copy, use, modify, create derivative works, display, (in whole or part), or act on such content without additional approval or consideration, in any form, media, or technology now known or later developed for the full term of any rights that may exist in such content.
Revisions to These Terms and Conditions
Daiichi Sankyo may at any time revise these Terms and Conditions by updating this posting. You are bound by any such revisions and should therefore periodically visit this page to review the then current Terms and Conditions to which you are bound.
Help lower patients’ co-pay
Along with lowering co-pays over time, Daiichi Sankyo will pay for up to 3 add-on generic antihypertensives for patients that do not reach BP goal while on an olmesartan-based medication.*Learn More
Hypertension Care offers powerful
products, valuable patient programs,
and educational support.
BENICAR, AZOR, and TRIBENZOR are indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which these drugs principally belong. There are no controlled trials demonstrating risk reduction with BENICAR, AZOR, or TRIBENZOR.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals.
BENICAR HCT is indicated for the treatment of hypertension. BENICAR HCT is not indicated for initial therapy.
BENICAR, BENICAR HCT, AZOR, and TRIBENZOR can be used alone or with other antihypertensive agents.
AZOR is indicated as initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals.
Initial therapy with AZOR is not recommended in patients ≥75 years of age or in hepatically impaired patients.
TRIBENZOR is not indicated for the initial therapy of hypertension.
BENICAR®, BENICAR HCT®, AZOR®, and TRIBENZOR® Important Safety Information
WARNING: FETAL TOXICITY
- When pregnancy is detected, discontinue BENICAR, BENICAR HCT, AZOR, or TRIBENZOR as soon as possible
- Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See WARNINGS AND PRECAUTIONS: Fetal Toxicity
Please see the following Important Safety Information for BENICAR:
Morbidity in Infants
Children <1 year of age must not receive BENICAR for hypertension. Drugs that act directly on the renin-angiotensin-aldosterone system (RAAS) can have effects on the development of immature kidneys.
Please see the following Important Safety Information for BENICAR, BENICAR HCT, AZOR, and TRIBENZOR:
Do not co-administer aliskiren with BENICAR, BENICAR HCT, AZOR, or TRIBENZOR in patients with diabetes.
Pregnancy Category D
Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue BENICAR, BENICAR HCT, AZOR, or TRIBENZOR as soon as possible.
Hypotension in Volume- or Salt-Depleted Patients
In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (eg, those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with BENICAR, BENICAR HCT, AZOR, or TRIBENZOR. Treatment should start under close medical supervision.
Impaired Renal Function
In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. There has been no long-term use of olmesartan medoxomil in patients with unilateral or bilateral renal artery stenosis, but similar results may be expected.
Non-Steroidal Anti-Inflammatory Agents
In patients who are elderly, volume-depleted (including those on diuretics), or with compromised renal function, co-administration of olmesartan medoxomil and NSAIDs, including COX-2 inhibitors, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in these patients. The antihypertensive effect of olmesartan medoxomil may be attenuated by NSAIDs, including COX-2 inhibitors.
Dual Blockade of the Renin-Angiotensin System (RAS)
Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Closely monitor blood pressure, renal function and electrolytes in patients on BENICAR, BENICAR HCT, AZOR, or TRIBENZOR and other agents that affect the RAS.
Avoid use of aliskiren with BENICAR, BENICAR HCT, AZOR, or TRIBENZOR in patients with renal impairment (GFR <60 mL/min).
Concurrent Use with Colesevelam Hydrochloride
Concurrent administration of bile acid sequestering agent colesevelam hydrochloride reduces the systemic exposure and peak plasma concentration of olmesartan. Consider administering olmesartan at least 4 hours before the colesevelam hydrochloride dose.
Avoid use while nursing; discontinue either nursing or the drug.
Due to the hydrochlorothiazide component, BENICAR HCT and TRIBENZOR have the following Important Safety Information:
BENICAR HCT and TRIBENZOR are contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.
Fetal/Neonatal Morbidity and Mortality
Thiazides cross the placental barrier and appear in cord blood. There is a risk of fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions that have occurred in adults.
Impaired Renal Function
BENICAR HCT is not recommended in patients with severe renal impairment. Avoid use of TRIBENZOR in patients with severely impaired renal function (creatinine clearance ≤30 mL/min). If progressive renal impairment becomes evident, consider withholding or discontinuing TRIBENZOR.
Thiazides may precipitate azotemia in patients with renal disease. Cumulative effects of the drug may develop in patients with impaired renal function.
Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Avoid use of TRIBENZOR in patients with severely impaired hepatic function.
Electrolyte and Metabolic Imbalances
Due to the hydrochlorothiazide component, observe patients for clinical signs of fluid or electrolyte imbalance.
Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history.
Systemic Lupus Erythematosus
Thiazide diuretics have been reported to cause exacerbation or activation of systemic lupus erythematosus.
Acute Myopia and Secondary Angle-Closure Glaucoma
Thiazides can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Discontinue hydrochlorothiazide as rapidly as possible in these patients. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.
Lithium generally should not be given with thiazides.
Due to the amlodipine component, AZOR and TRIBENZOR have the following Important Safety Information:
Although vasodilation attributable to amlodipine is gradual in onset, acute hypotension has rarely been reported after oral administration. Patients with severe aortic stenosis may be at particular risk.
Increased Angina and/or Myocardial Infarction
Patients, particularly those with severe obstructive coronary artery disease, may develop increased frequency, duration, or severity of angina or acute myocardial infarction on starting calcium channel blocker therapy or at the time of dosage increase.
Since amlodipine is extensively metabolized by the liver and the plasma elimination half-life (t1/2) is 56 hours in patients with severely impaired hepatic function, caution should be exercised when administering AZOR to patients with severe hepatic impairment. Initial therapy with AZOR is not recommended in hepatically impaired patients. Avoid use of TRIBENZOR in patients with severely impaired hepatic function.
Effect of Amlodipine on Simvastatin
Due to increased exposure to simvastatin, if simvastatin is co-administered with amlodipine, do not exceed doses of greater than 20 mg daily of simvastatin.
Elderly patients have decreased clearance of amlodipine. Initial therapy with AZOR is not recommended in patients ≥75 years old.
The withdrawal rates due to adverse reactions were similar with BENICAR and BENICAR HCT to placebo: BENICAR (2.4% vs 2.7%); BENICAR HCT (2.0% vs 2.0%).
The incidence of adverse reactions with BENICAR and BENICAR HCT was similar to placebo.
– The only adverse reaction that occurred in >1% of patients treated with BENICAR and more frequently than placebo was dizziness (3% vs 1%)
– Adverse reactions reported in >2% of patients taking BENICAR HCT and more frequently than placebo included nausea (3% vs 0%), hyperuricemia (4% vs 2%), dizziness (9% vs 2%), and upper respiratory tract infection (7% vs 0%)
The only adverse reaction that occurred in greater than or equal to 3% of patients treated with AZOR and more frequently than placebo was edema. The placebo-subtracted incidence was 5.7% (5/20 mg), 6.2% (5/40 mg), 13.3% (10/20 mg), and 11.2% (10/40 mg). The edema incidence for placebo was 12.3%.
Adverse reactions seen at lower rates but at about the same or greater incidence as in patients receiving placebo included hypotension, orthostatic hypotension, rash, pruritus, palpitation, urinary frequency, and nocturia.
In individual clinical trials of amlodipine and olmesartan medoxomil, other commonly reported adverse reactions included headache, dizziness, and flushing.
The most frequently reported adverse reaction was dizziness (5.8 to 8.9%). The other most frequent adverse reactions occurring in greater than or equal to 2% of patients treated with TRIBENZOR were peripheral edema (7.7%), headache (6.4%), fatigue (4.2%), nasopharyngitis (3.5%), muscle spasms (3.1%), nausea (3.0%), upper respiratory tract infection (2.8%), diarrhea (2.6%), urinary tract infection (2.4%), and joint swelling (2.1%).
There was a greater decrease in hemoglobin and hematocrit with AZOR compared to either component alone.
Dosage and Administration
No initial dosage adjustments are recommended with BENICAR in elderly or in moderate to marked renal impairment (creatinine clearance <40 mL/min)/hepatic dysfunction.
– In patients with possible depletion of intravascular volume (eg, patients on diuretics, particularly with impaired renal function), BENICAR should be initiated under close medical supervision and consideration given to use of a lower starting dose
BENICAR HCT is not indicated for initial therapy. Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.
Initial therapy with AZOR is not recommended in patients ≥75 years old or in hepatically impaired patients.
TRIBENZOR is not indicated for initial therapy. Avoid use of TRIBENZOR in patients with severely impaired hepatic function and in patients with severely impaired renal function (creatinine clearance ≤30 mL/min).
Trademarks not owned by Daiichi Sankyo, Inc., are property of their respective owners.